Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


COMMENTWIRE: Breo approved in COPD, but others are breathing down its neck

This article was originally published in Scrip

Executive Summary

GlaxoSmithKline can push ahead with a new franchise in COPD (and possibly asthma) but it really only has months to go before the competition starts to get out there on the market. 

You may also be interested in...

Respiratory Effectiveness Group Summit: real-life use of COPD, asthma treatments

The recent Respiratory Effectiveness Group (REG) Summit provided clinicians, general practitioners, pulmonologists, and representatives from the industry with the opportunity to discuss real-life effectiveness research in respiratory disease. Dr Natasha Spiller was there to look at a new battle ground for top-selling mainstay respiratory therapies, Spiriva, Symbicort and Advair.

BI, GSK, Novartis hale and hearty at COPD party

It has been an eventful week in chronic obstructive pulmonary disease (COPD). New safety data emerged for Spiriva Respimat (tiotropium; Boehringer Ingelheim) and encouraging analyses from Novartis’ LABA/LAMA Ultibro Breezhaler from the European Respiratory Society (ERS) Annual Congress: while Anoro (umeclidinium/vilanterol), GlaxoSmithKline’s fixed-dose long-acting beta 2 agonist/long-acting muscarinic antagonist (LABA/LAMA) inhaler, has been recommended for approval by the US FDA Pulmonary-Allergy Drugs Advisory Committee (PADAC).

European Ultibro nod gives Novartis boost in COPD race

The expected entry of Ultibro Breezhaler into the COPD market following the positive opinion issued by the European Medicines Agency's Committee for Medicinal Products for Human Use on 25 July will considerably advance Novartis's position within the market.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts